Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

$7.8 Billion Molecular Diagnostics Market Positioned for Significant Growth

Published: Wednesday, July 10, 2013
Last Updated: Wednesday, July 10, 2013
Bookmark and Share
New analysis sizes the MDx market, analyzes key market drivers, and provides detailed forecasts through 2015 across major sectors.

G2 Intelligence announces the release of U.S. Molecular Diagnostic and Genomic Testing 2013-2015: Laboratory Industry Analysis, Trends, and Forecasts, a new resource for stakeholders in MDx testing. In conjunction with the release of the study, G2 currently gauges the MDx market at $7.8 billion in 2013.

“Like other health care sectors, molecular diagnostics is experiencing disruptive forces that are redefining the very core of care, delivery, and reimbursement models,” according to L. Eleanor Herriman, M.D. M.B.A., Managing Director of G2 Intelligence Advisory Services, and one of the report’s analysts. “These forces are largely driven by the reactions of health care payers and policy makers to the national health care cost crisis, and the shift to a value-based system. MDx is uniquely positioned to play a central role in value-based health care, but must first navigate some challenging regulatory and payer issues.”

U.S. Molecular Diagnostic and Genomic Testing clarifies the market with:

•    Market sizing and growth forecasts through 2015 across seven MDx sectors:
o    Hematology-Oncology (Hem-Onc)
o    Pharmacogenomics (PGx)
o    Women’s Health
o    General Infectious
o    Inherited
o    Transplant
o    Blood Screening

•    Analysis of key market drivers and inhibitors

•    Platform usage by test type including:

o    Abbott, ABI, Access, Autogenomics, BD (Becton, Dickinson and Company), Bio Rad Biocare, Cepheid, Dako, Focus, GenMark, Gen-Probe, Leica, Luminex Qiagen, Roche, Ventana and more

•    Menu availability and in-house vs. send out analysis, by test including:

o    Adenovirus, ALK, BCL-2, BCR/ABL, BK Virus, Bordetella, BRAF, C-Diff, Chlamydia/Gonorrhea, C-KIT, CMV Cytomegalovirus, Cystic Fibrosis, EBV (Epstein-Barr), EGFR, Enterovirus, FLT3, Group A Strep, Group B Strep,HBV Viral Load, HCV Viral Load and Genotyping, HER-2, Herpes (HSV), HIV Viral Load and Genotyping, HPV, HPV Genotyping, HPV non-cervical, Influenza A/B, JAK-2, KI-67, KRAS, MRSA or SA, Norovirus, Respiratory Virus, Trich, Tuberculosis, VRE, VZV (Varicella Zoster)

•    How and why Pharmacogenomics is poised to grow

•    Next Generation Sequencing challenges and solutions

•    And much more...

“Where there is volatility, there is opportunity,” says Jennifer Musumeci, MS, and Associate Director of G2’s Advisory Services. “While there is significant variability in growth rates within MDx sectors, the overall market will expand in 2013, despite the bumpy road in the short term. It’s essential for labs, IVD manufacturers, health care payers and providers to find out where they stand, and where these game-changing diagnostics are headed. This new report fills that void with a wealth of valuable data.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos